New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 18, 2012
10:00 EDTPJC, EIX, QUAD, SYK, SWK, STJ, SKUL, RDS.A, POT, HAL, DB, CMA, CSX, ABTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abbott (ABT) downgraded to Market Perform from Outperform at Raymond James... CSX (CSX) downgraded to Hold from Buy at Deutsche Bank... Comerica (CMA) downgraded to Neutral from Buy at Sterne Agee... Deutsche Bank (DB) downgraded to Underweight from Neutral at JPMorgan... Halliburton (HAL) downgraded to Equal Weight from Overweight at Stephens... Potash (POT) downgraded to Sector Perform from Outperform at RBC Capital... Royal Dutch Shell (RDS.A) downgraded to Sell from Neutral at Goldman... Skullcandy (SKUL) downgraded to Market Perform from Strong Buy at Raymond James... St. Jude Medical (STJ) downgraded to Hold from Buy at Canaccord...Stanley Black & Decker (SWK) downgraded to Market Perform from Outperform at Raymond James... Stryker (SYK) downgraded to Perform from Outperform at Oppenheimer... Quad/Graphics (QUAD) downgraded to Underperform at Sector Perform at RBC Capital... Edison International (EIX) downgraded to Neutral from Buy at Citigroup... Piper Jaffray (PJC) downgraded to Hold from Buy at Sandler O'Neill.
News For A;SKUL;STJ;SWK;SYK;QUAD;EIX;PJC From The Last 14 Days
Check below for free stories on A;SKUL;STJ;SWK;SYK;QUAD;EIX;PJC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
07:45 EDTSTJSt. Jude Medical management to meet with Deutsche Bank
Subscribe for More Information
July 22, 2014
16:04 EDTSKULSkullcandy names David Raffone as Chief Sales and Revenue Officer
Subscribe for More Information
08:36 EDTSYKStryker appoints CEO Kevin Lobo as chairman
Subscribe for More Information
08:02 EDTSTJSt. Jude announces FlexAbility Ablation Catheter CE Mark approval, first use
St. Jude Medical CE Mark approval and first use of the FlexAbility Ablation Catheter. Designed with feedback from physician thought-leaders around the world, the FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design. The next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through its ability to bend and conform to the cardiac anatomy, decreasing the amount of pressure distributed to a patientís heart wall while simultaneously increasing the stability of therapy delivery.
July 18, 2014
09:00 EDTSYKStryker price target raised to $92 from $87 at RW Baird
Baird raised its price target on Stryker to $92 from $87 citing valuation, organic sales growth, and solid risk/reward. The firm has an Outperform rating on the stock.
July 17, 2014
16:09 EDTSYKStryker sees Q3 adjusted EPS $1.12-$1.16 , consensus $1.16
"If foreign currency exchange rates hold near current levels, we do not expect the impact on third quarter or full year net sales to be significant," the company said.
16:08 EDTSYKStryker sees FY14 adjusted EPS $4.75-$4.80, consensus $4.80
Now projecting full year organic sales growth to be in the range of 5.0%-6.0%, consensus $9.61B.
16:07 EDTSYKStryker reports Q2 adjusted EPS $1.08, consensus $1.08
Subscribe for More Information
15:26 EDTSYKNotable companies reporting after market close
Subscribe for More Information
06:20 EDTAAgilent initiated with a Neutral at Citigroup
Target $64.
July 16, 2014
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
July 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
08:00 EDTSTJSt. Jude Medical management to meet with Leerink
Meeting to be held in New York on July 22 hosted by Leerink.
July 14, 2014
09:05 EDTSTJSt. Jude Medical to acquire NeuroTerm for approximately $200M in cash
St. Jude Medical has signed a definitive agreement to acquire privately held NeuroTherm, a manufacturer of interventional pain management therapies, for approximately $200M in cash. NeuroTherm is involved in the treatment of spinal pain using radiofrequency ablation, a segment of the chronic pain market in which St. Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately $10M-$15M to St. Jude Medicalís 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St. Jude Medicalís consolidated EPS in 2014 and accretive thereafter on a GAAP basis.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use